Immune Therapy of HPV-induced Cancers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

January 31, 2015

Study Completion Date

May 31, 2015

Conditions
HPV-induced Cancers
Interventions
BIOLOGICAL

P16_37-63

100 ug per application subcutaneously, mixed with 0.3 ml Montanide ISA-51 VG; once a week for four weeks, followed by a 4 week rest period (1 cycle), up to 3 cycles

Trial Locations (1)

60488

Krankenhaus Nordwest, Frankfurt am Main

All Listed Sponsors
lead

Oryx GmbH & Co. KG

INDUSTRY

NCT01462838 - Immune Therapy of HPV-induced Cancers | Biotech Hunter | Biotech Hunter